Get the Stockscreener App
2.11
1.44%
0.03
Pre-market:
2.11
Nkarta Inc stock is traded at $2.11, with a volume of 904.50K.
It is up +1.44% in the last 24 hours and up +1.93% over the past month.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
See More
Previous Close:
$2.08
Open:
$2.08
24h Volume:
904.50K
Relative Volume:
1.10
Market Cap:
$149.86M
Revenue:
-
Net Income/Loss:
$-117.50M
P/E Ratio:
-0.8792
EPS:
-2.4
Net Cash Flow:
$-114.31M
1W Performance:
-12.45%
1M Performance:
+1.93%
6M Performance:
-0.47%
1Y Performance:
-31.49%
1-Day Range:
$2.07
$2.1795
1-Week Range:
$2.035
$2.4399
52-Week Range:
$1.31
$3.8099
Nkarta Inc Stock (NKTX) Company Profile
Name
Nkarta Inc
Sector
Industry
Phone
(925) 407-1049
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
2.11 | 147.73M | 0 | -117.50M | -114.31M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-14-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-22-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Jul-28-22 | Initiated | Needham | Buy |
| Jul-18-22 | Initiated | SVB Leerink | Outperform |
| Mar-11-22 | Initiated | Raymond James | Outperform |
| Mar-08-22 | Initiated | H.C. Wainwright | Buy |
| Jan-06-22 | Initiated | William Blair | Outperform |
| Nov-18-21 | Initiated | SMBC Nikko | Outperform |
| Jul-16-21 | Initiated | Oppenheimer | Outperform |
| Aug-04-20 | Initiated | Cowen | Outperform |
| Aug-04-20 | Initiated | Evercore ISI | Outperform |
| Aug-04-20 | Initiated | Mizuho | Buy |
| Aug-04-20 | Initiated | Stifel | Buy |
View All
Nkarta Inc Stock (NKTX) Latest News
Nkarta Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Nkarta Inc. stock prediction for this weekEarnings Performance Report & Weekly High Return Stock Opportunities - newser.com
Will Nkarta Inc. stock deliver strong dividend growthWeekly Stock Recap & Free Expert Verified Stock Movement Alerts - newser.com
Risk adjusted return profile for Nkarta Inc. analyzedWeekly Risk Report & Capital Efficiency Focused Strategies - newser.com
Real time alert setup for Nkarta Inc. performanceEarnings Overview Summary & AI Powered Buy/Sell Recommendations - newser.com
Will Nkarta Inc. stock gain from government policiesPortfolio Update Summary & Safe Capital Investment Plans - newser.com
Using Python tools to backtest Nkarta Inc. strategies2025 Support & Resistance & Free Technical Pattern Based Buy Signals - newser.com
Nkarta Inc Stock Analysis and ForecastGrowth vs. Value Investing & Low Cost Market Strategies - earlytimes.in
Weiss Ratings Reaffirms "Sell (D-)" Rating for Nkarta (NASDAQ:NKTX) - MarketBeat
Is Nkarta Inc. stock supported by strong fundamentalsJuly 2025 Levels & Low Risk High Reward Trade Ideas - newser.com
What drives Nkarta Inc stock priceRisk Mitigation Techniques & Low Entry Cost Investments - earlytimes.in
Can machine learning forecast Nkarta Inc. recoveryJuly 2025 Weekly Recap & High Accuracy Investment Signals - newser.com
Nkarta Inc. stock chart pattern explainedProduct Launch & Short-Term Trading Opportunity Alerts - newser.com
Will Nkarta Inc. stock sustain high P E ratiosJuly 2025 Action & Expert Curated Trade Setups - newser.com
Will Nkarta Inc. stock continue upward momentumMarket Movement Recap & AI Powered Market Entry Strategies - newser.com
Nkarta to Participate in November Investor Conferences - Bluefield Daily Telegraph
Nkarta (NKTX) to Release Earnings on Thursday - MarketBeat
What momentum indicators show for Nkarta Inc. stockTrade Signal Summary & Expert Approved Momentum Ideas - newser.com
Nkarta, Inc. Advances CAR NK Cell Therapy Study for Immune-Mediated Diseases - MSN
Why Nkarta Inc. stock is a must watch in 20252025 Buyback Activity & Fast Momentum Stock Entry Tips - fcp.pa.gov.br
Is Nkarta Inc. stock a defensive play in 2025Weekly Stock Analysis & Community Consensus Trade Signals - fcp.pa.gov.br
Nkarta’s NKX019 Study: A Promising Step in Autoimmune Disease Treatment - TipRanks
Nkarta Inc Stock (NKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):